TY - JOUR
T1 - Obsessive-compulsive symptoms in patients with schizophrenia
T2 - Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life
AU - Wu, Tzu Hua
AU - Chiu, Chih Chiang
AU - Chen, Po Yu
AU - Huang, Ming Chyi
AU - Chen, Chun Hsin
AU - Shen, Winston W.
AU - Lu, Mong Liang
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Obsessive-compulsive symptoms (OCS) occur in a substantial portion of schizophrenia patients and have significant impacts on clinical course. This study was intended to investigate the relationships of OCS with pharmacological parameters of olanzapine, psychopathology, and quality of life. Totally 151 schizophrenia patients were recruited, and rated using Yale-Brown Obsessive-Compulsive scale (YBOCS), Positive and Negative Syndrome Scale (PANSS), Montgomery-Åsberg Depression Rating Scale (MADRS), and World Health Organization Questionnaire on Quality of Life: Short Form (WHOQOL-BREF). The concentrations of olanzapine and N-desmethylolanzapine were determined by HPLC. Twenty-five patients (16.6%) revealed the presence of OCS. OCS group had significantly higher olanzapine dose, more numbers of past hospitalizations, higher PANSS total, positive, negative, and general psychopathology scores, and higher MADRS score than those in non-OCS group. The WHOQOL-BREF physical subscale score in schizophrenia patients with OCS was significantly lower. Olanzapine dose, PANSS score, and MADRS score were significantly correlated with YBOCS score. Our findings highlight that OCS is highly prevalent in schizophrenia patients under olanzapine treatment, especially those at high doses. Schizophrenia patients with OCS had higher severity of psychotic and depressive symptoms and poorer quality of life. Clinicians should monitor OCS in patients with schizophrenia receiving olanzapine treatment.
AB - Obsessive-compulsive symptoms (OCS) occur in a substantial portion of schizophrenia patients and have significant impacts on clinical course. This study was intended to investigate the relationships of OCS with pharmacological parameters of olanzapine, psychopathology, and quality of life. Totally 151 schizophrenia patients were recruited, and rated using Yale-Brown Obsessive-Compulsive scale (YBOCS), Positive and Negative Syndrome Scale (PANSS), Montgomery-Åsberg Depression Rating Scale (MADRS), and World Health Organization Questionnaire on Quality of Life: Short Form (WHOQOL-BREF). The concentrations of olanzapine and N-desmethylolanzapine were determined by HPLC. Twenty-five patients (16.6%) revealed the presence of OCS. OCS group had significantly higher olanzapine dose, more numbers of past hospitalizations, higher PANSS total, positive, negative, and general psychopathology scores, and higher MADRS score than those in non-OCS group. The WHOQOL-BREF physical subscale score in schizophrenia patients with OCS was significantly lower. Olanzapine dose, PANSS score, and MADRS score were significantly correlated with YBOCS score. Our findings highlight that OCS is highly prevalent in schizophrenia patients under olanzapine treatment, especially those at high doses. Schizophrenia patients with OCS had higher severity of psychotic and depressive symptoms and poorer quality of life. Clinicians should monitor OCS in patients with schizophrenia receiving olanzapine treatment.
KW - Depression
KW - Obsessive-compulsive symptoms
KW - Olanzapine
KW - Psychopathology
KW - Quality of life
KW - Yale-Brown Obsessive-Compulsive scale
UR - http://www.scopus.com/inward/record.url?scp=85064078521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064078521&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2019.03.007
DO - 10.1016/j.psychres.2019.03.007
M3 - Article
AN - SCOPUS:85064078521
SN - 0165-1781
VL - 276
SP - 1
EP - 5
JO - Psychiatry Research
JF - Psychiatry Research
ER -
